: Since the introduction of rituximab in the late 1990s, significant progress has been made in advancing targeted therapies for B cell lymphomas, improving patients' chance of being cured and clinicians' therapeutic armamentarium. A better understanding of disease biology and pathogenic pathways, coupled with refinements in immunophenotypic and molecular diagnostics, have been instrumental in these achievements. While traditional chemotherapy remains fundamental in most cases, concerns surrounding chemorefractoriness and cumulative toxicities, particularly the depletion of the hemopoietic reserve, underscore the imperative for personalized treatment approaches. Integrating targeted agents, notably monoclonal antibodies, alongside chemotherapy has yielded heightened response rates and prolonged survival. A notable paradigm shift is underway with innovative-targeted therapies replacing cytotoxic drugs, challenging conventional salvage strategies like stem cell transplantation. This review examines the landscape of emerging targets for lymphoma cells and explores innovative therapies for diffuse large B cell lymphoma (DLBCL). From Chimeric Antigen Receptor-T cells to more potent monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, checkpoint inhibitors, and small molecules targeting intracellular pathways, each modality offers promising avenues for therapeutic advancement. This review aims to furnish insights into their potential implications for the future of DLBCL treatment strategies.

D'Alo', F., Bellesi, S., Maiolo, E., Alma, E., Bellisario, F., Malafronte, R., Viscovo, M., Campana, F., Hohaus, S., Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas, <<CANCERS>>, 2024; 16 (12): N/A-N/A. [doi:10.3390/cancers16122243] [https://hdl.handle.net/10807/282157]

Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas

D'Alo', Francesco
;
Bellesi, Silvia;Maiolo, Elena;Alma, Eleonora;Bellisario, Flaminia;Malafronte, Rosalia;Viscovo, Marcello;Campana, Fabrizia;Hohaus, Stefan
2024

Abstract

: Since the introduction of rituximab in the late 1990s, significant progress has been made in advancing targeted therapies for B cell lymphomas, improving patients' chance of being cured and clinicians' therapeutic armamentarium. A better understanding of disease biology and pathogenic pathways, coupled with refinements in immunophenotypic and molecular diagnostics, have been instrumental in these achievements. While traditional chemotherapy remains fundamental in most cases, concerns surrounding chemorefractoriness and cumulative toxicities, particularly the depletion of the hemopoietic reserve, underscore the imperative for personalized treatment approaches. Integrating targeted agents, notably monoclonal antibodies, alongside chemotherapy has yielded heightened response rates and prolonged survival. A notable paradigm shift is underway with innovative-targeted therapies replacing cytotoxic drugs, challenging conventional salvage strategies like stem cell transplantation. This review examines the landscape of emerging targets for lymphoma cells and explores innovative therapies for diffuse large B cell lymphoma (DLBCL). From Chimeric Antigen Receptor-T cells to more potent monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, checkpoint inhibitors, and small molecules targeting intracellular pathways, each modality offers promising avenues for therapeutic advancement. This review aims to furnish insights into their potential implications for the future of DLBCL treatment strategies.
2024
Inglese
D'Alo', F., Bellesi, S., Maiolo, E., Alma, E., Bellisario, F., Malafronte, R., Viscovo, M., Campana, F., Hohaus, S., Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas, <<CANCERS>>, 2024; 16 (12): N/A-N/A. [doi:10.3390/cancers16122243] [https://hdl.handle.net/10807/282157]
File in questo prodotto:
File Dimensione Formato  
D_Alò Cancers 2024.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 438.4 kB
Formato Adobe PDF
438.4 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/282157
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact